This trial is evaluating whether OAV101 will improve 7 primary outcomes and 3 secondary outcomes in patients with Atrophy. Measurement will happen over the course of 12 months.
This trial requires 24 total participants across 1 different treatment group
This trial involves a single treatment. OAV101 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
"Muscular atrophy is an inherited condition. All families with muscular atrophy are related to a common ancestor, and the affected gene is localised to chromosome 12q21.1." - Anonymous Online Contributor
"Muscular atrophy is a nonspecific finding that may be observed when the biopsy shows muscle involvement with myxomatous degenerated muscle fibers containing sarcoplasmic reticulum accumulations but not fibrosis. Muscle-associated conditions do not cause muscular atrophy, nor do muscular abnormalities cause muscle wasting. This latter finding is the common artifact of a muscle biopsy showing myopathic change (i.e. muscle cells contain more than two fiber types)." - Anonymous Online Contributor
"Symptoms of muscular atrophy include difficulty moving or lifting items, weakness in muscles, and lack of stamina. Patients with muscle atrophy have trouble moving things like the table they sat on, or picking up the plates on the plate above the microwave. These patients have a weakness in their arms, hands, and legs. They also have poor endurance. This can also present as poor stamina during sporting activity. These symptoms are visible only by physical inspection by an expert.\n" - Anonymous Online Contributor
"Very few treatments have been found to be effective for the treatment of muscular atrophy. No medications are available for the treatment of muscular atrophy. There is no proven medical or cosmetic value to performing surgery. Exercise is an alternative treatments for many cases of muscular atrophy, even if it cannot be proved to work to cure the condition of muscular atrophy.\n" - Anonymous Online Contributor
"Around 11 million Americans have a diagnosis of muscular atrophy every year. The incidence of muscular atrophy increases with age and is highest in men 75 years and older." - Anonymous Online Contributor
"Even in the postoperative period, MAF patients who are overweight might have a significant risk of relapse after their operations. On the other hand, patients who are overweight or obese have no or only a slight risk of relapse postoperatively." - Anonymous Online Contributor
"Muscular atrophy is a disease of old age in which muscle mass is diminished, muscle fibers are smaller, and the number of muscle fibers is diminished. It is the principal cause of muscle weakness of old age. It can lead to progressive muscle weakening that becomes progressively more severe as old age continues. It is the leading medical diagnosis in old age as the primary disease causing progressive muscular weakness. Muscular atrophy is present in many types of weakness as well as in chronic fatigue syndrome. There are several other diseases with muscular weakness as a feature." - Anonymous Online Contributor
"Currently there were about half of the oav101 clinical trials for therapeutic use. There are many new therapy options. Oav101 continues to be a reliable therapy for ovoidal benign tumours and benign paralyses. Ovine regenerative medicine continues to be an important adjunct to limb salvage surgery. Further clinical trials using oav101 in traumatic limb loss are planned. oav101 has been shown to have a regenerative effect on injured muscle and tendon. Oav101 remains a promising adjunct to surgical therapy in ovoidal benign tumours. Oav101 has been shown to be an effective in situ therapy for acute paralysis when surgically applied. Oav103 is also currently under development." - Anonymous Online Contributor
"An orally administered form of oav101 had proven to increase muscle volume and strength in an older population by a higher percentage than a placebo at one month post-treatment. The oav101-mediated effects were greater than those from the placebo. This is because of the increased size of both muscle fibers and muscle masses." - Anonymous Online Contributor
"O-O-Ave101 is effective in the treatment of muscular atrophy, resulting in significant improvements in both quality of life and fatigue. Further studies are warranted to determine the long-term impact of O-O-Ave101 treatment." - Anonymous Online Contributor
"Muscle atrophy is the term to describe those changes that result in skeletal muscle loss, particularly those changes in the skeletal muscle associated with a reduction in its growth potential. This occurs even in skeletal muscle with less satellite cell content (Type II fibers) due to the lack of satellite cell stimulation or re-growth after muscle injury or disuse. In this scenario, it is impossible to rehabilitate or to recover muscular strength. The use of growth factors or other methods of stimulating satellite cell proliferation and proliferation-stimulating factor may hopefully offer a new therapeutic option for the management of skeletal muscle atrophic disorders." - Anonymous Online Contributor
"On average, the time of diagnosis is 9.1 years later for men than women. In a cohort of all cases diagnosed from 2002 to 2006, the onset of muscular atrophy is relatively early and mostly affects the anterior compartment of the lower extremities and legs." - Anonymous Online Contributor